Sumey, C. J., Fischer, S., Perez-Gracia, J. L., Pook, D. W., Mellado, B., Mateo, J., Matsubara, N., Lee, J. L., Bilen, M. A., Appleman, L. J., Kelly, W. K., Gauna, D. C., Siddiqui, B. A., Wang, K., Smith, K. M., Arrington, L., Mukherjee, S., Mir, O., Khan, H. M. (2026). Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5070